Low Immune Cross-Reactivity between West Nile Virus and a Zika Virus Vaccine Based on Modified Vaccinia Virus Ankara
Zika virus (ZIKV) is a mosquito-borne flavivirus whose infection in pregnant women is associated with a spectrum of birth defects, which are together referred as Congenital Zika Syndrome. In addition, ZIKV can also induce Guillain–Barré syndrome, which is an autoimmune disease with neurological symp...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-03-01
|
| Series: | Pharmaceuticals |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1424-8247/15/3/354 |
| _version_ | 1797443690547904512 |
|---|---|
| author | Nereida Jiménez de Oya Patricia Pérez Ana-Belén Blázquez Estela Escribano-Romero Mariano Esteban Juan-Carlos Saiz Juan García-Arriaza Miguel A. Martín-Acebes |
| author_facet | Nereida Jiménez de Oya Patricia Pérez Ana-Belén Blázquez Estela Escribano-Romero Mariano Esteban Juan-Carlos Saiz Juan García-Arriaza Miguel A. Martín-Acebes |
| author_sort | Nereida Jiménez de Oya |
| collection | DOAJ |
| description | Zika virus (ZIKV) is a mosquito-borne flavivirus whose infection in pregnant women is associated with a spectrum of birth defects, which are together referred as Congenital Zika Syndrome. In addition, ZIKV can also induce Guillain–Barré syndrome, which is an autoimmune disease with neurological symptoms. The recent description of the first local infections of ZIKV in the European continent together with the expansion of one of its potential vectors, the Asian tiger mosquito <i>(Aedes albopictus)</i>, invite us to be prepared for future outbreaks of ZIKV in this geographical region. However, the antigenic similarities of ZIKV with other flaviviruses can lead to an immune cross-reactivity with other circulating flaviviruses inducing, in some cases, flavivirus-disease exacerbation by antibody-dependent enhancement (ADE) of infection, which is a major concern for ZIKV vaccine development. Until now, West Nile virus (WNV) is the main medically relevant flavivirus circulating in the Mediterranean Basin. Therefore, anticipating the potential scenario of emergency vaccination against ZIKV in areas of Europe where WNV is endemic, in this investigation, we have evaluated the cross-reactivity between WNV and our previously developed ZIKV vaccine candidate based on modified vaccinia virus Ankara (MVA) vector expressing ZIKV structural proteins (MVA-ZIKV). To this end, mice were first immunized with MVA-ZIKV, subsequently challenged with WNV, and then, the ZIKV- and WNV-specific immune responses and protection against WNV were evaluated. Our results indicate low cross-reactivity between the MVA-ZIKV vaccine candidate and WNV and absence of ADE, supporting the safety of this ZIKV vaccine candidate in areas where the circulation of WNV is endemic. |
| first_indexed | 2024-03-09T13:00:41Z |
| format | Article |
| id | doaj.art-5570ea74af0e4d90b72f0e7bdaaf9b56 |
| institution | Directory Open Access Journal |
| issn | 1424-8247 |
| language | English |
| last_indexed | 2024-03-09T13:00:41Z |
| publishDate | 2022-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceuticals |
| spelling | doaj.art-5570ea74af0e4d90b72f0e7bdaaf9b562023-11-30T21:54:55ZengMDPI AGPharmaceuticals1424-82472022-03-0115335410.3390/ph15030354Low Immune Cross-Reactivity between West Nile Virus and a Zika Virus Vaccine Based on Modified Vaccinia Virus AnkaraNereida Jiménez de Oya0Patricia Pérez1Ana-Belén Blázquez2Estela Escribano-Romero3Mariano Esteban4Juan-Carlos Saiz5Juan García-Arriaza6Miguel A. Martín-Acebes7Department of Biotechnology, Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria (INIA), Consejo Superior de Investigaciones Científicas (CSIC), 28040 Madrid, SpainCentro Nacional de Biotecnología (CNB), Consejo Superior de Investigaciones Científicas (CSIC), 28049 Madrid, SpainDepartment of Biotechnology, Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria (INIA), Consejo Superior de Investigaciones Científicas (CSIC), 28040 Madrid, SpainDepartment of Biotechnology, Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria (INIA), Consejo Superior de Investigaciones Científicas (CSIC), 28040 Madrid, SpainCentro Nacional de Biotecnología (CNB), Consejo Superior de Investigaciones Científicas (CSIC), 28049 Madrid, SpainDepartment of Biotechnology, Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria (INIA), Consejo Superior de Investigaciones Científicas (CSIC), 28040 Madrid, SpainCentro Nacional de Biotecnología (CNB), Consejo Superior de Investigaciones Científicas (CSIC), 28049 Madrid, SpainDepartment of Biotechnology, Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria (INIA), Consejo Superior de Investigaciones Científicas (CSIC), 28040 Madrid, SpainZika virus (ZIKV) is a mosquito-borne flavivirus whose infection in pregnant women is associated with a spectrum of birth defects, which are together referred as Congenital Zika Syndrome. In addition, ZIKV can also induce Guillain–Barré syndrome, which is an autoimmune disease with neurological symptoms. The recent description of the first local infections of ZIKV in the European continent together with the expansion of one of its potential vectors, the Asian tiger mosquito <i>(Aedes albopictus)</i>, invite us to be prepared for future outbreaks of ZIKV in this geographical region. However, the antigenic similarities of ZIKV with other flaviviruses can lead to an immune cross-reactivity with other circulating flaviviruses inducing, in some cases, flavivirus-disease exacerbation by antibody-dependent enhancement (ADE) of infection, which is a major concern for ZIKV vaccine development. Until now, West Nile virus (WNV) is the main medically relevant flavivirus circulating in the Mediterranean Basin. Therefore, anticipating the potential scenario of emergency vaccination against ZIKV in areas of Europe where WNV is endemic, in this investigation, we have evaluated the cross-reactivity between WNV and our previously developed ZIKV vaccine candidate based on modified vaccinia virus Ankara (MVA) vector expressing ZIKV structural proteins (MVA-ZIKV). To this end, mice were first immunized with MVA-ZIKV, subsequently challenged with WNV, and then, the ZIKV- and WNV-specific immune responses and protection against WNV were evaluated. Our results indicate low cross-reactivity between the MVA-ZIKV vaccine candidate and WNV and absence of ADE, supporting the safety of this ZIKV vaccine candidate in areas where the circulation of WNV is endemic.https://www.mdpi.com/1424-8247/15/3/354West Nile virusZika virusMVAvaccinecross-protectionimmunogenicity |
| spellingShingle | Nereida Jiménez de Oya Patricia Pérez Ana-Belén Blázquez Estela Escribano-Romero Mariano Esteban Juan-Carlos Saiz Juan García-Arriaza Miguel A. Martín-Acebes Low Immune Cross-Reactivity between West Nile Virus and a Zika Virus Vaccine Based on Modified Vaccinia Virus Ankara Pharmaceuticals West Nile virus Zika virus MVA vaccine cross-protection immunogenicity |
| title | Low Immune Cross-Reactivity between West Nile Virus and a Zika Virus Vaccine Based on Modified Vaccinia Virus Ankara |
| title_full | Low Immune Cross-Reactivity between West Nile Virus and a Zika Virus Vaccine Based on Modified Vaccinia Virus Ankara |
| title_fullStr | Low Immune Cross-Reactivity between West Nile Virus and a Zika Virus Vaccine Based on Modified Vaccinia Virus Ankara |
| title_full_unstemmed | Low Immune Cross-Reactivity between West Nile Virus and a Zika Virus Vaccine Based on Modified Vaccinia Virus Ankara |
| title_short | Low Immune Cross-Reactivity between West Nile Virus and a Zika Virus Vaccine Based on Modified Vaccinia Virus Ankara |
| title_sort | low immune cross reactivity between west nile virus and a zika virus vaccine based on modified vaccinia virus ankara |
| topic | West Nile virus Zika virus MVA vaccine cross-protection immunogenicity |
| url | https://www.mdpi.com/1424-8247/15/3/354 |
| work_keys_str_mv | AT nereidajimenezdeoya lowimmunecrossreactivitybetweenwestnilevirusandazikavirusvaccinebasedonmodifiedvacciniavirusankara AT patriciaperez lowimmunecrossreactivitybetweenwestnilevirusandazikavirusvaccinebasedonmodifiedvacciniavirusankara AT anabelenblazquez lowimmunecrossreactivitybetweenwestnilevirusandazikavirusvaccinebasedonmodifiedvacciniavirusankara AT estelaescribanoromero lowimmunecrossreactivitybetweenwestnilevirusandazikavirusvaccinebasedonmodifiedvacciniavirusankara AT marianoesteban lowimmunecrossreactivitybetweenwestnilevirusandazikavirusvaccinebasedonmodifiedvacciniavirusankara AT juancarlossaiz lowimmunecrossreactivitybetweenwestnilevirusandazikavirusvaccinebasedonmodifiedvacciniavirusankara AT juangarciaarriaza lowimmunecrossreactivitybetweenwestnilevirusandazikavirusvaccinebasedonmodifiedvacciniavirusankara AT miguelamartinacebes lowimmunecrossreactivitybetweenwestnilevirusandazikavirusvaccinebasedonmodifiedvacciniavirusankara |